Zeta Surgical Reports Mixed Reality Navigation System Receives FDA Special 510(k) Clearance for Expanded Functionality

Zeta Surgical

Zeta Surgical, a surgical robotics and mixed reality company, announced today that its Zeta Cranial Navigation System has received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded functionality through enhanced software features and compatibility with additional accessories.

Zeta Cranial Navigation System

The Zeta Surgical Cranial Navigation System is a mixed-reality navigation system for neurosurgery, providing surgeons with “GPS-like” guidance with millimetric accuracy in real-time. Zeta’s computer vision engine ensures maintained accuracy by automatically registering multiple times a second, accounting for patient movement, and allowing for awake and non-immobilized use in both operative and extra-operative settings. The platform received its first 510(k) clearance from the U.S. FDA in September 2023.

Dr. Roman Stolyarov, Chief Product Officer of Zeta Surgical, commented on the clearance:

“This new FDA clearance enables key enhancements in usability and performance, bringing us closer to achieving our mission of dramatically reducing the barriers to surgical navigation and unlocking its benefits for a wider array of patients and procedures.”

“We are thrilled to scale Zeta’s deployments in the U.S., building on its early successes in clinics,” said Jose Amich, Co-Founder and CEO of Zeta Surgical. “We look forward to seeing Zeta’s impact on patient outcomes and in the field of neuroscience.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


Tabrecta is the first FDA-approved therapy to treat non small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
The Cor® TRICUSPID ECM® valve has been successfully implanted in the 11th patient enrolled in the expansion by Dr. Marc Gerdisch, Chief of Cardiothoracic Surgery at Franciscan Health Heart Center in Indianapolis, Indiana & principal investigator for the adult component of the study.
Thirona notes LungQ 3.0.0 builds on 10 years of clinical trials and 200+ publications to deliver advanced segmentation of pulmonary segments and subsegments.
The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.
Gabriel Sanchez, Ph.D., CEO and co-founder of Enspectra Health. "This significant achievement is the result of the excellent work by the Enspectra Health team and our clinical advisors. Our submission was cleared by the FDA ahead of plan, underscoring our ability to successfully drive an innovative technology from concept to clearance."

By using this website you agree to accept Medical Device News Magazine Privacy Policy